FDA Clearance Tracker · DEN110012
APTIMA TRICHOMONAS VAGINALIS ASSAY
Last checked: Nov 20, 2026Latest source record: Apr 19, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Apr 19, 2011
De Novo granted
Time to decision
6 days
Received Apr 13, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Post-NSE
Device class
Class II
The decision
- FDA number
- DEN110012
- Device name
- APTIMA TRICHOMONAS VAGINALIS ASSAY
- Applicant
- Gen-Probe Incorporated
- Applicant location
- San Diego, CA
- Received
- Apr 13, 2011
- Decided
- Apr 19, 2011
- Decision
- De Novo granted
- Submission type
- Post-NSE
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3860
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN110012
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Gen-Probe Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- APTIMA HPV ASSAYPMA supplement
P100042-S038 · Decided Feb 3, 2026 · 271 days after receipt · Panel Track
Device type: Kit, rna detection, human papillomavirus (OYB) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.